Tag: intelligence

VICTORIA, Seychelles, 27 juill. 2025 (GLOBE NEWSWIRE) -- Bitget, première bourse de cryptomonnaies et société Web3, connaît une explosion de la demande depuis le lancement de GetAgent, le tout premier assistant de trading IA natif au monde dédié aux cryptomonnaies. En seulement quelques jours, GetAgent a fait sensation dans l’univers crypto, générant une participation record des utilisateurs, un engouement viral sur les réseaux sociaux et une importante destruction de jetons.

LUXEMBOURG, July 26, 2025 (GLOBE NEWSWIRE) -- As investor focus shifts away from large-cap cryptocurrencies with limited upside, early-stage projects with real-world utility and scalable technology are gaining traction. One such project is Bitcoin Swift (BTC3), a next-generation blockchain protocol currently in its presale phase. With a fixed price of $1.00 during Stage 1 and a confirmed $15.00 launch target, Bitcoin Swift is positioning itself as a notable entry in the 2025 crypto landscape.

SHANGHAI, China, July 26, 2025 (GLOBE NEWSWIRE) -- Pony AI Inc. (“Pony.ai” or the “Company”) (Nasdaq: PONY), a global leader in achieving large-scale commercialization of autonomous mobility, today announced that it has received a permit to provide fully driverless commercial Robotaxi services of Shanghai’s Pudong New Area, issued at the World Artificial Intelligence Conference (“WAIC”) 2025. This achievement demonstrates not only increasing regulatory trust and recognition in the Company’s technology and safety standards, but also represents another major milestone in advancing Robotaxi commercialization in a top-tier urban market in China.

With America’s aging power grid teetering on the brink of collapse, CrowdPoint Technologies President Nadab U. Akhtar has issued a powerful call to arms: it’s time to stop maintaining the grid—and start commanding it.

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.